Palatin Technologies (NYSEAMERICAN:PTN) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.26, Fidelity Earnings reports. The firm had revenue of $60.27 million for the quarter.
PTN stock opened at $1.06 on Friday. Palatin Technologies has a 12-month low of $0.59 and a 12-month high of $1.78.
PTN has been the topic of a number of analyst reports. Zacks Investment Research lowered Palatin Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, August 27th. LADENBURG THALM/SH SH set a $3.00 price target on Palatin Technologies and gave the company a “buy” rating in a research report on Thursday, May 23rd. Finally, HC Wainwright set a $8.00 price target on Palatin Technologies and gave the company a “buy” rating in a research report on Monday, June 24th.
About Palatin Technologies
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted, receptor-specific therapeutics for the treatment of various diseases in the United States. The company's principal product is Vyleesi, an on demand subcutaneous injectable product that has completed Phase III clinical studies for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder.
Recommended Story: What are the advantages to having securities held in street name?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.